EI
SPRY icon

Ellevest Inc’s ARS Pharmaceuticals SPRY Stock Holding History

Ellevest Inc’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-243
Closed -$1.58K – 1442
2023
Q1 		$1.58K Hold
243
– – ﹤0.01% 1495
2022
Q4 		$2.07K Hold
243
– – ﹤0.01% 1382
2022
Q3 		$1K Hold
243
– – ﹤0.01% 1521
2022
Q2 		$1K Buy
+243
New +$847 ﹤0.01% 1318

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ellevest Inc's SPRY Position: Q2 2023 in Review

Ellevest Inc sold out of ARS Pharmaceuticals (SPRY) in Q2 2023, closing a stake of 243 shares — an estimated $1.58K sold.

Ellevest Inc first reported a position in SPRY in Q2 2022 and held it in 4 quarters. The position peaked at $2.07K in Q4 2022. 92 funds tracked by Wall St. Rank hold SPRY as of Q2 2023.

  • Ellevest Inc reported no remaining ARS Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ellevest Inc sold 243 ARS Pharmaceuticals shares in Q2 2023, an estimated $1.58K.
  • Ellevest Inc first reported a position in ARS Pharmaceuticals in Q2 2022 and held it in 4 quarters.
  • Ellevest Inc's ARS Pharmaceuticals position peaked at $2.07K in Q4 2022.
  • 92 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.